The industry is shifting from broad capacity expansion to specialized, technology-driven partnerships that emphasize deep expertise in biologics, peptides, high-potency drugs, ADCs, and cell/gene therapies.

AI and digital manufacturing are becoming integral, enabling faster development timelines, predictive quality control, and digital twins to optimize processes and troubleshoot issues.

The biologics CDMO market is dynamic, expected to grow from about $32.2 billion in 2025 to roughly $103.1 billion by 2035 as complexity and regulatory demands rise.

Across the globe, the CDMO market is expanding rapidly—projected to reach about $369 billion by 2034 from a 2025 baseline near $197 billion—driven by demand for biologics, peptides, ADCs, and advanced therapies.

Future leaders will blend scale with specialized expertise, regulatory excellence, and close customer collaboration, making CDMOs central to pharma innovation and resilience.

Pharmaceutical manufacturing is shifting from in-house production to integrated CDMO partnerships spanning development, clinical manufacturing, and commercial production.

Drivers of the CDMO wave include localization pressures, tariff and supply-chain considerations, easier financing, and a shift toward depth-focused capabilities rather than broad end-to-end services.

Technology transfer between lab and commercial scales remains a challenge, underscoring the need for robust digital analytics, real-time data sharing, and disciplined capacity management to avoid overcapacity.

Investments are flowing into regionalized, technology-intensive capacity, with notable commitments such as Lilly/Resilience funding for US device manufacturing, Evonik expansion, and several new or expanded facilities for peptide and biologics work.

Smaller and virtual biotech firms benefit from outsourcing to access specialized capabilities without heavy internal capital outlays.

Recent moves illustrate the shift: Lonza expanded a U.S. partnership on two biologics programs, while Samsung Biologics' CHF 1.46 billion bid for PolyPeptide CDMO aims to broaden peptide and biologics capabilities.